Cleo Diagnostics (ASX:COV) Cash, Cash Equivalents, Marketable Securities : A$10.11 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Cash, Cash Equivalents, Marketable Securities?

Cleo Diagnostics's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (A$0.80 Mil) to Jun. 2023 (A$0.24 Mil) but then increased from Jun. 2023 (A$0.24 Mil) to Dec. 2023 (A$10.11 Mil).

Cleo Diagnostics's annual cash, cash equivalents, marketable securities stayed the same from . 20 (A$0.00 Mil) to . 20 (A$0.00 Mil) but then increased from . 20 (A$0.00 Mil) to Jun. 2023 (A$0.24 Mil).

Cleo Diagnostics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Cleo Diagnostics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Cash, Cash Equivalents, Marketable Securities Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Cash, Cash Equivalents, Marketable Securities

0.24

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Cash, Cash Equivalents, Marketable Securities	0.80	0.24	10.11

Cleo Diagnostics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Cleo Diagnostics (ASX:COV) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Cleo Diagnostics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines